Breakdown | |||||
TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
78.56M | 70.01M | 59.58M | 53.91M | 46.47M | 41.59M | Gross Profit |
43.43M | 43.15M | 47.95M | 43.08M | 35.87M | 30.94M | EBIT |
3.57M | 6.13M | 8.72M | 11.34M | 7.86M | 8.89M | EBITDA |
9.31M | 11.80M | 12.56M | 18.48M | 14.70M | 11.85M | Net Income Common Stockholders |
7.22M | 9.95M | 9.96M | 12.48M | 9.78M | 9.33M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
21.39M | 20.25M | 115.46M | 128.24M | 123.60M | 116.01M | Total Assets |
201.43M | 196.64M | 186.10M | 188.38M | 179.98M | 168.42M | Total Debt |
796.00K | 1.01M | 1.20M | 1.40M | 1.28M | 926.78K | Net Debt |
-10.20M | -9.30M | -56.33M | -50.16M | -35.71M | -48.28M | Total Liabilities |
11.88M | 14.21M | 16.07M | 10.13M | 14.20M | 12.39M | Stockholders Equity |
189.55M | 182.43M | 170.03M | 178.25M | 165.78M | 156.04M |
Cash Flow | Free Cash Flow | ||||
9.91M | 12.75M | 17.58M | 13.93M | 14.63M | 8.33M | Operating Cash Flow |
11.74M | 13.32M | 21.86M | 17.90M | 19.20M | 10.91M | Investing Cash Flow |
-32.04M | -53.97M | 7.37M | 4.30M | -26.74M | -75.51M | Financing Cash Flow |
-5.74M | -6.57M | -23.27M | -7.62M | -4.68M | 102.37M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $1.95B | ― | -0.25% | ― | 9.37% | 95.72% | |
70 Outperform | $547.42M | 76.18 | 3.96% | 0.88% | 21.49% | -31.23% | |
67 Neutral | $1.46B | 66.88 | 1.73% | ― | 3.00% | ― | |
61 Neutral | $1.92B | ― | -43.33% | ― | 22.29% | -32.89% | |
54 Neutral | $5.38B | 3.40 | -45.06% | 3.28% | 16.75% | -0.02% | |
53 Neutral | $199.82M | ― | -60.75% | ― | 4.66% | 11.33% |
On June 11, 2025, Simulations Plus announced preliminary revenue figures for its third fiscal quarter, expecting between $19 million and $20 million, and updated its full-year revenue guidance to range between $76 million and $80 million. The company is facing market uncertainties impacting its pharmaceutical and biotech clients, leading to budget cuts and project delays. In response, Simulations Plus has reorganized its operations to a functionally driven model and made key leadership appointments to enhance client engagement and sales capabilities, aiming for long-term growth and operational efficiency.
The most recent analyst rating on (SLP) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Simulations Plus stock, see the SLP Stock Forecast page.
On May 30, 2025, Simulations Plus, Inc. announced a restructuring of its operations, which included reducing its workforce by approximately 10%, or 23 employees, to enhance operational efficiency and reduce expenses. This restructuring is expected to incur charges of about $0.7 million but aims to save approximately $4.3 million annually. Additionally, the company made significant leadership changes, including appointing John DiBella as Chief Revenue Officer, while other executives assumed new roles to support the company’s strategic goals.
The most recent analyst rating on (SLP) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Simulations Plus stock, see the SLP Stock Forecast page.
On April 3, 2025, Simulations Plus reported its financial results for the second quarter of fiscal 2025, which ended on February 28, 2025. The company experienced a 23% increase in total revenue, reaching $22.4 million, with software revenue rising by 16% and services revenue by 34%. Despite a decrease in net income and diluted EPS compared to the previous year, the company maintained its full-year revenue guidance of $90 to $93 million and adjusted diluted EPS of $1.07 to $1.20. The strong performance was driven by significant growth in its Quantitative Systems Pharmacology business unit and robust services revenue, particularly in Medical Communications. Simulations Plus is optimistic about maintaining its momentum into the second half of 2025, despite challenges in the biopharma funding environment.